Literature DB >> 8691139

T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation.

R Dyall1, D H Fremont, S C Jameson, J Nikolić-Zugić.   

Abstract

We investigated mechanistic differences in antigen presentation between murine MHC class I variants H-2K(b) and H-2K(bm)8. H-2K(bm)8 differs from H-2K(b) by four residues at the floor of the peptide-binding site, affecting its B pocket which interacts with the second (P2) residue of the peptide. The rest of the molecule, including the T cell receptor (TCR)-contacting residues, is identical to H-2K(b). Due to this variation, CTLs that recognize the ovalbumin 257-264 and HSV gB 498-505 peptides on H-2K(b) cannot recognize them on H-2K(bm)8. This could be due to impaired peptide binding or an altered peptide: K(bm)8 conformation. Peptide binding studies ruled out the first explanation. Molecular modeling indicated that the most obvious consequence of amino acid variation between peptide/H-2K(b) and peptide/H-2K(bm)8 complexes would be a loss of the conserved hydrogen bond network in the B pocket of the latter. This could cause conformational variation of bound peptides. Intermolecular second-site reversion was used to test this hypothesis: P2-substituted OVA and HSV peptides, engineered to restore the hydrogen bond network of the B pocket, were the only ones which restored CTL recognition. These results provide a molecular understanding of peptide/MHC conformational variation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691139      PMCID: PMC2192691          DOI: 10.1084/jem.184.1.253

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2.

Authors:  D R Madden; D N Garboczi; D C Wiley
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

2.  Positive selection of the T-cell repertoire is affected by mutations in the peptide-binding site of MHC class I molecules.

Authors:  J Nikolić-Zugić; R Dyall
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

3.  Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove.

Authors:  D H Fremont; E A Stura; M Matsumura; P A Peterson; I A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705.

Authors:  H C Guo; D R Madden; M L Silver; T S Jardetzky; J C Gorga; J L Strominger; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

Review 5.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Minor pocket B influences peptide binding, peptide presentation and alloantigenicity of H-2Kb.

Authors:  T J Yun; M D Tallquist; E M Rohren; J M Sheil; L R Pease
Journal:  Int Immunol       Date:  1994-07       Impact factor: 4.823

7.  Single-residue changes in class I major histocompatibility complex molecules stimulate responses to self peptides.

Authors:  A G Grandea; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

8.  Peptide variants reveal how antibodies recognize major histocompatibility complex class I.

Authors:  K A Hogquist; A G Grandea; M J Bevan
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

9.  CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens.

Authors:  R Dyall; L V Vasović; A Molano; J Nikolić-Zugić
Journal:  Int Immunol       Date:  1995-08       Impact factor: 4.823

10.  Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity.

Authors:  S Chattopadhyay; M Theobald; J Biggs; L A Sherman
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Allopeptides and the alloimmune response.

Authors:  Ankit Bharat; T Mohanakumar
Journal:  Cell Immunol       Date:  2007-07       Impact factor: 4.868

2.  Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Authors:  José A Guevara-Patiño; Manuel E Engelhorn; Mary Jo Turk; Cailian Liu; Fei Duan; Gabrielle Rizzuto; Adam D Cohen; Taha Merghoub; Jedd D Wolchok; Alan N Houghton
Journal:  J Clin Invest       Date:  2006-04-13       Impact factor: 14.808

3.  Structural basis for the restoration of TCR recognition of an MHC allelic variant by peptide secondary anchor substitution.

Authors:  Michael J Miley; Ilhem Messaoudi; Beatrix M Metzner; Yudong Wu; Janko Nikolich-Zugich; Daved H Fremont
Journal:  J Exp Med       Date:  2004-11-22       Impact factor: 14.307

4.  Tolerance to the neuron-specific paraneoplastic HuD antigen.

Authors:  Ilana DeLuca; Nathalie E Blachère; Bianca Santomasso; Robert B Darnell
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

5.  Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL).

Authors:  P A Smith; A Brunmark; M R Jackson; T A Potter
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

6.  Heteroclitic immunization induces tumor immunity.

Authors:  R Dyall; W B Bowne; L W Weber; J LeMaoult; P Szabo; Y Moroi; G Piskun; J J Lewis; A N Houghton; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.